ImmunityBio (IBRX) Cash from Investing Activities (2016 - 2025)
ImmunityBio (IBRX) has disclosed Cash from Investing Activities for 12 consecutive years, with $43.6 million as the latest value for Q4 2025.
- Quarterly Cash from Investing Activities rose 343.09% to $43.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$149.8 million through Dec 2025, down 1123.26% year-over-year, with the annual reading at -$149.8 million for FY2025, 1123.26% down from the prior year.
- Cash from Investing Activities for Q4 2025 was $43.6 million at ImmunityBio, up from -$181.4 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $116.7 million in Q2 2022, with the low at -$181.4 million in Q3 2025.
- Average Cash from Investing Activities over 5 years is -$12.5 million, with a median of -$4.8 million recorded in 2022.
- The sharpest move saw Cash from Investing Activities plummeted 1926.4% in 2021, then skyrocketed 1012.33% in 2022.
- Over 5 years, Cash from Investing Activities stood at -$137.8 million in 2021, then skyrocketed by 86.29% to -$18.9 million in 2022, then surged by 111.9% to $2.2 million in 2023, then surged by 337.26% to $9.8 million in 2024, then soared by 343.09% to $43.6 million in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods came in at $43.6 million, -$181.4 million, and -$16.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.